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Cystic Fibrosis-Related Diabetes 
(CFRD)
Manfred Ballmann
Abstract
Cystic fibrosis-related diabetes (CFRD) is the most frequent comorbidity in 
CF. The prevalence is age-dependent and abnormalities in/of glucose homeostasis 
start early in life. As CFRD has an impact on pulmonary function and life expec-
tancy, early diagnosis and treatment is mandatory. Screening is needed because 
initially, most patients with CFRD do not show any typical symptoms of diabetes. 
The question of which screening method gets the best results is still under discus-
sion. For treatment insulin is recommended but a relevant percentage of patients do 
not use it, and even if insulin is used, there is no consensus on what the best insulin 
regime in the case of CFRD is. Recently, oral antidiabetic drugs were shown to be 
as effective and safe as insulin in the initial treatment of CFRD. This treatment 
might reduce the additional treatment burden for patients with CFRD. The best 
way to monitor CFRD is also under discussion (HbA1c and/or continuous glucose 
monitoring; CGM). The threshold of HbA1c might be lower than for other types of 
diabetes. As patients with CF become older, the duration of CFRD will also increase 
and typical diabetes complications will occur. So far, these are mainly microvascular 
complications. The new CFTR modulators might influence not only pulmonary 
function but potentially also glucose homeostasis.
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1. Introduction
CF is a multi-organ disease that also affects the exocrine and endocrine pancreas 
[1]. CFRD is a discrete entity of type 3 Diabetes mellitus, displaying aspects from 
both type 1 Diabetes mellitus and type 2 Diabetes mellitus. It is the most frequent 
comorbidity in CF involving around 31% of CF patients older than 18 years [2] and 
up to more than 40% in those older than 30 years [3]. It results from involvement 
of the endocrine pancreatic function and is the end stage of early onset impaired 
glucose homeostasis [4]. Today, additional CFRD is still a risk factor for decreased 
pulmonary function but no longer for increased mortality [3]. In the past, an 
increased mortality, in part depending on sex and severe CFTR mutation, was 
observed [5]. Several aspects of the disease’s pathophysiology are not yet completely 
understood [6], but some new insights might help to understand the process [7]. 
Clinically, there is a need for screening since earlier prospective studies regarding 
CFRD showed that most CF patients exhibited no clinical signs of hyperglycemia at 
the time they were diagnosed with CFRD by oral glucose tolerance tests (OGTTs) 
[8]. The advantages and disadvantages of different screening approaches will be 
discussed. Even after diagnosis, there is some discussion on how to treat patients 
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with CFRD diagnosed by screening. Guidelines recommended insulin treatment [9] 
but registry data from the US [2] and Europe [10] showed that a relevant proportion 
of CF patients with CFRD are not treated with daily insulin. Alternative treatment 
options might be needed, and a recent study demonstrated that oral antidiabetic 
drugs are not inferior to insulin regarding HbA1c over 2 years after CFRD was 
diagnosed by annual OGTT screening [11]. Upcoming CFTR modulator treat-
ment is an interesting area regarding glucose homeostasis and CFRD. The results 
of two small case studies [12, 13] on CF patients treated with ivacaftor imply that 
there is a possibility that CFTR modulation might also influence insulin secretion. 
Additionally, a registry study showed a trend to a reduced prevalence of CFRD in 
those treated with ivacaftor for a longer time [14]. In another case study with five 
patients (F508 del homozygous) treated with lumacaftor/ivacaftor, no consistent 
effect on glucose tolerance or insulin secretion was observed [15]. Overall, there are 
a number of important aspects of CFRD, from its pathophysiology to screening, 
diagnosis, treatment, best methods of follow-up, and new perspectives with CFTR 
modulator treatment options.
2. CFRD and epidemiology
2.1 Prevalence and incidence and risk factors
In 1994, a first study reporting the prevalence of CFRD was published [16]. 
Prevalence was 14.7% in all Danish CF patients. More recent data from the CFF 
patient registry showed an age-dependent prevalence from around 2% in those 
younger than 10 years up to around 40–50% in adults [2]. The prevalence is in the 
same range as reported from Germany (Table 1) [17] as a European country. The 
prevalence varies between different European countries based on a recent report 
of the ECFS patient registry [18]. While diabetes prevalence has risen, incidence 
has fallen significantly: from 4 cases per 100 patient-years during the 1998–2002 
interval to 2.7 cases per 100 patient-years between 2003 and 2008, representing a 
40% decrease in the number of diabetes diagnoses in the US [3]. In a longitudinal 
study from the UK, the incidence was 3.5% (observation period 1996–2005) [19].
Severe genotype, pancreatic insufficiency, and female gender remain consider-
able intrinsic risk factors for early acquisition of CFRD [18]. In a large prospective 
study with 1093 patients, impaired fasting glucose, impaired glucose tolerance, and 
indeterminate glucose tolerance were all predictors of future CFRD [20] .
2.2 Sex differences and mortality
An increased mortality used to be described mainly for female CF patients with 
CFRD [21]. Mortality rate decreased from 1992–1997 to 2003–2008 in females from 
Diabetes in CF 0–5 
years
6–11 
yeas
12–17 
years
18–29 
years
30–39 
years
>40 
years
Diabetes 0.1 1.2 11.1 21.6 32.0 46.6
Of these CFRD 0.0 100 86.7 96.5 94.5 94.3
Of these not CFRD 0.1 0.0 13.3 3.6 5.5 5.7
Adapted from table 17 and table 18 [17].
Table 1. 
Frequency in % of CF patients with diabetes in 2018.
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6.9 to 3.2 deaths per 100 patient-years and in male subjects from 6.5 to 3.8 deaths 
per 100 patient-years. There was no longer a sex difference in mortality [3]. A 
follow-up study (2008–2012) from the same CF center reported that there still was 
a sex difference in adults, but only in severe genotypes with higher prevalence of 
CFRD, resulting in an increased mortality in females [22]. Consequently, there is 
still a discussion about the gender influence on CFRD and survival.
2.3 Genetics
Since the CF gene was detected, there has been the question of a CFTR muta-
tion/mutation class-related risk for CFRD or whether there are other mutations 
outside of the CFTR gene that may modify the risk of developing CFRD.
In a longitudinal study from the UK, CFTR mutation classes I and II were shown 
to increase the risk of CFRD independently of other known risk factors [19]. A 
more recent study reported the risk for CFRD and mortality in adults studied in 
the years 2008–2012 [22]. CFRD was associated with increased mortality indepen-
dently of mutation category (mild or severe) [22].
A study looking for CFRD frequency in different age groups and the influence 
of mutation classes of the CFTR gene found that the prevalence of CFRD increased 
with age from 2.6% in patients <18 years to 22.1% in patients 18 years or older in 
those homozygous for group II (including del phen 508, the most frequent CFTR 
mutation) mutations. It was only 1.5% in patients 18 years or older in group IV/any 
CFTR mutations [23]. In general, group IV mutations are less severe than class II 
mutations and this results also in a low risk for CFRD. If CFRD as a complication of 
CF has developed, there is still an increased mortality risk even in mild mutation 
classes (e.g., CFTR mutation class IV), but the risk for developing CFRD is higher in 
severe CFTR mutation classes (e.g., CFTR mutation class I or II).
2.3.1 Genetic modifiers
The frequency of HLA types related to type 1 or type 2 diabetes were in the 
same range in CF patients with or without diabetes. There was also no difference in 
frequency compared to normal population [23]. As for other comorbidities, there 
are also modifiers for CFRD. Susceptibility to CFRD is at least in part determined by 
variants at SLC26A9 and at four loci associated with type 2 diabetes in the general 
population [24]. In a very recent study, a wide overlap with genetic modifiers of 
type 2 diabetes was described [25]. This might allow for a stratification of CFRD 
screening. Those with less risk depending on CFTR mutation classes and modifier 
genes might be screened starting at an older age and less frequently than those with 
a high risk for CFRD.
3. CFRD and pathophysiology
The mechanism of how diabetes develops in CF is not yet completely under-
stood. Difficult access to animal models and human pancreatic tissue may con-
tribute to this situation. Two recent reviews focused on the pathogenesis of CFRD 
[26, 27]. Insulin secretion is reduced even with normal OGTT and this is observed 
even in kids [28]. Insulin sensitivity is not or only minimally impaired apart from 
severe infections or systemic glucocorticoid treatment [29]. An often-discussed 
question concerned the possible existence of a direct influence of CFTR on α or 
β-cells. In an elegant study, murine models of β-cell CFTR deletion and human 
pancreas and islets from controls and CF patients were used [7]. There were some 
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important results: (1) In the murine cell model, CFTR did not affect β-cell func-
tion. (2) In human islets, nearly no expression of CFTR mRNA was detected. (3) 
Additionally, there was no CFTR protein or electrical activity. (4) The secretion of 
islet hormones (insulin and glucagon) was in the normal range and only minimal 
changes in important islet-regulatory transcripts were detected. (5) As a conse-
quence of inflammation, only 35% of β-cell area was conserved and the other part 
of the islet was compounded by immune infiltration. Overall, CFRD seems to be a 
consequence of beta-cell loss, accompanied by inflammation of the islets. There is 
no reason to think that CFTR mutations directly cause islet dysfunction [7].
4. CFRD and diagnosis
4.1 Screening, initial symptoms, and outcome
As there are usually no typical diabetes-related symptoms [8], there is a need 
to screen for CFRD. Guidelines recommended a regular oral glucose tolerance test 
(OGTT) for screening [9]. Annual screening should start at the age of 10 years, as 
recommended in the US and by the ECFS, or at 12 years, as recommended in the 
UK. Because OGTT is time-consuming for patients and CF center staff, there is 
some interest in more comfortable alternative methods. The screening rate with 
OGTT in CF is nowhere near the recommendations in guidelines. In median, only 
61.3% of CF patients aged 10–17 years and only 32.8% of adults were screened by 
OGTT in the US [2]. Nevertheless, it is possible to increase the rate of screening by 
OGTT, as shown from a program in a pediatric CF center that increased its annual 
screening rate for outpatients from 45% to 71% [30].
In a registry study, it has recently been reported that CF centers that screen 
more frequently for CFRD detected CFRD earlier and that those that screened less 
often had a faster decrease in pulmonary function [31]. This supports the view that 
screening for CFRD is an important tool to optimize CF care.
4.1.1 HbA1c for screening
HbA1c is quickly collected and simple to measure, which makes it a comfortable 
test for both patients and CF center staff. To reduce the need for OGTT, the question 
was whether HbA1c was able to identify those patients at risk for CFRD. However, 
because of low sensitivity to detect CFRD, HbA1c has not been recommended as 
a screening tool for CFRD [32] for many years. This has recently become contro-
versial. If a low HbA1c (<5.5%) as threshold was used to identify CF patients with 
CFRD, the sensitivity covered a wide range from 93% [33] to only 78% [34]. As of 
now, there is not enough evidence that HbA1c is a reliable tool to screen for CFRD.
4.1.2 Different OGTT methods
To make OGTT more comfortable for patients and staff, different modifications 
of the OGTT procedure were investigated. A shorter sample time (1 h) [35, 36] was 
discussed, as well as a lower glucose load (50 g) [37]. Both approaches need evalua-
tion in a larger cohort. So far, standard (WHO) OGTT is still recommended.
4.1.3 Continuous glucose monitoring (CGM)
Another way to uncover impaired glucose homeostasis and CFRD even earlier 
than using OGTT is CGM. OGTTs were compared with 6 days of CGM in detecting 
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glucose disturbance in 30 CF patients (age: 10–18 years). CGM identified glucose 
changes that had been missed by OGTT. This might help to initiate treatment of 
glucose disturbance before CFRD is diagnosed [38]. However, since even OGTT 
is only rarely used in many CF centers there is no reason to expect that the more 
sophisticated CGM will be used more frequently.
4.1.4 OGTT performance and diagnostic criteria
• OGTT: Glucose 1.75 g/kg body weight in 250–300 ml water max 75 g glucose 
drinking in 5 min
• Performed after >8 h of fasting in the morning.
• No physical activity during the test.
• Often the OGTT is done during the annual assessment. No other investigations 
during the OGTT (such as an ultrasound) are allowed.
• Blood glucose is measured before (0 min) and 60 min and 120 min after drink-
ing the glucose load.
5. CFRD and treatment
5.1 Treatment
Disturbance of glucose homeostasis starts early in life, CFRD being the end stage 
[4]. This opens the discussion on the best time to start treatment even before CFRD 
is diagnosed by OGTT. Insulin is the only recommended treatment. This should be 
accompanied by an education program and dietary advice. Despite recommendations, 
insulin is used only in around 75% of all CFRD patients all over the world [2, 17, 40].
5.1.1 Insulin
Insulin is the recommended treatment for CFRD. There are two problems with 
this recommendation. (1) A relevant percentage of CFRD patients do not use 
insulin (see Table 2). This is the case in the US [2], the UK [41], and Germany [17] 
at least, as the national registers documented. All these are registries sponsored 
by CF organizations. Data from a German/Austrian general diabetes registry [42] 
that collects data from both CFRD patients and type 1 and 2 diabetes patients have 
shown that only 77% of CFRD patients were on insulin [40]. There might be several 
reasons for this. First of all, most patients do not realize symptoms of hyperglyce-
mia early in the course of CFRD [8]. Secondly, CF treatment is an enormous burden 
for adult CF patients and families [43] as well as for children with CF. They spent 
74 min a day with treatment, compared to type 1 diabetes with 56 min and asthma 
with 6 min [44]. Perhaps they like to avoid this additional burden of insulin treat-
ment. (2) The optimal insulin regime is not defined and different regimes are in use. 
This includes long-term once-daily insulin, intensified insulin treatment several 
times a day, or an insulin pump with continuous insulin and pushes with meals. The 
more intensive insulin treatment with a pump is less in use, at least in adolescents 
and young adults, compared to type 1 diabetes patients in the same age range [45]. 
In adult CFRD patients treated with insulin, the mean daily dose was not different 
to matched type 1 or type 2 diabetes patients [46].
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One single optimal insulin regime for all CFRD patients does not exist, since 
individual adjustment to medical needs and patients’ options is required. The treat-
ment of CFRD is a team approach including dieticians, diabetologists, psycholo-
gists, and the CF physician.
5.1.2 Oral antidiabetic drugs
Oral antidiabetic drugs have been used in CFRD for many years [47]. The group 
of sulfonylurea (glibenclamide) had some disadvantages. They showed inhibitions 
of CFTR Cl channels in vitro [48–50]. The non-sulfonylurea hypoglycemic agent 
repaglinide showed only a weak inhibition of CFTR Cl channels [51]. In 2001, a study 
was published that showed postprandial effects of premeal insulin lispro and premeal 
repaglinide on postprandial glucose levels in humans. Glucose decreased (peak, 2 h and 5 
h AUC) with insulin lispro, and glucose decreased with repaglinide only 5 h AUC. Insulin 
secretion (5 h AUC) increased only with insulin lispro [52]. In the latest Cochrane review 
regarding the use of oral antidiabetic drugs in CFRD, published in 2016, it was concluded 
that controlled prospective studies are needed [53]. There are two prospective random-
ized controlled trials comparing the effects of insulin versus repaglinide in patients with 
newly diagnosed CFRD [11, 54]. In a 12-month trial, there was a significant increase in 
BMI only in the insulin group. Comparing the insulin to the repaglinide group, there 
was no significant difference in BMI, HbA1c, or pulmonary function changes over the 
study period [54]. In the other study over 24 months, there was no difference between 
the groups (insulin and repaglinide) regarding HbA1c, BMI, and pulmonary function. It 
was concluded from that study that at least a subgroup of patients with newly diagnosed 
CFRD can be treated initially with oral antidiabetic drugs [11]. This might be an option 
for those who refuse insulin due to the additional treatment burden (Table 3).
Indication therapy in case of 
CFRD
0–5 
years
6–11 
yeas
12–17 
years
18–29 
years
30–39 
years
>40 
years
Insulin 100 72.7 64.0 67.6 76.9 75.7
Oral antidiabetics 0 9.1 11.0 9.3 9.3 8.8
Dietary measures 0 27.3 39.0 21 25 23.3
Adapted from table 22 and table 23 [17].
Table 3. 
Frequency in % of CF patients with indication therapies related to diabetes in 2018.
Blood glucose mmol/l (mg/dl)
Start 60 min 120 min
Normal glucose tolerance (NGT) <5·6 (100) <11·1 (200) <7·8 (140)
Fasting hyperglycemia (FH) >5·6 (100) and <7·0 (126) <11·1 (200) <7·8 (140)
Impaired glucose tolerance (IGT) <7·0 (126) <11·1 (200) >7·8 (140)
<11·1 (200)
Indeterminate glycemia (INDET) <7·0 (126 ) >11·1 (200) <7·8 (140)
Diabetes (CFRD) without FH <7·0 (126) – >11·1 (200)
CFRD with FH ≥7·0 (126) – >11·1 (200)
Adapted from [39].
Table 2. 
Classification of glucose tolerance.
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5.1.3 Diet
The well-known diet restrictions and advice for type 1 or type 2 diabetes are 
not transferable to CFRD. In CFRD, the patients need a high-caloric nutrition, in 
contrast to what is recommended in other types of diabetes. Therefore, a dietician 
trained in CFRD is needed to support the patient with detailed information regard-
ing nutrition in the special situation of CFRD [55].
5.2 Treatment monitoring
5.2.1 HbA1c
HbA1c is not recommended to diagnose CFRD (see Section 4.1.1.). The situation 
is different for monitoring CFRD. HbA1c is used to monitor glycemic control in 
CFRD. In CFRD, the target value for HbA1c should be lower than in type 1 diabetes, 
because in CFRD mean plasma glucose does not correlate with HbA1c[56] . This is, 
for example, incorporated in the Australian Standards of Care for CFRD [57]. Adults 
with CFRD have a significantly lower HbA1c value compared to type 1 diabetes 
adults (6.8% vs. 7.9%) [58]. How low HbA1c values should be to prevent long-term 
diabetic comorbidities like microangiopathies (see also Section 6.1) is unknown.
5.2.2 CGM
A more strict control of glucose homeostasis with insulin treatment is achievable 
with CGM and is accompanied by an improved clinical outcome [59]. This requires the 
cooperation of the entire CFRD team and particularly the support by a diabetologist.
In general, adherence to diabetes care guidelines (ADA/CFF) is suboptimal [40] 
and improvement is urgently needed.
6. CFRD and complications
6.1 Microvascular complications
With decreased mortality, CF patients spend more years living with 
CFRD. Today, CF patients tend to develop microvascular complications, much like 
patients with type 1 or type 2 diabetes [60]. In long-standing CFRD (>10 years) 
with fasting hyperglycemia, 14% of patients had microalbuminuria and 16% had 
retinopathy [61]. The percentage of patients with hypertension was lower in adult 
CFRD patients while the percentage of patients suffering from nephropathy was 
higher compared to type 1 and 2 diabetes [58]. These data underline the need for 
routine screening for CFRD complications.
6.1.1 Retinal complications
More sophisticated eye investigations demonstrated changes at the retina level.
Screening for this kind of complication should be also mandatory [62]. 
Percentage of patients with retinopathy did not differ between adults with CFRD 
and type 1 or type 2 diabetes [58].
6.1.2 Macrovascular complications
Macrovascular complications have not been described so far. However, with 
increasing duration of CFRD in older CF patients, this kind of complication has 
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to be expected. Even microvascular complications develop later in CFRD than 
in other types of diabetes.
6.2 Risk for hyperglycemia
The risk for acute severe hyperglycemia exists but the condition is very rare 
[63]. Most CFRD patients do not develop a ketoacidosis. This might be related 
to residual insulin secretion and glucagon counter regulation. Hyperglycemia 
measured by HbA1c is a risk factor for mortality. In a prospective observational 
study, a HbA1c ≥ 6.5% was associated with a threefold increased risk of death [64]. 
Measuring HbA1c is mandatory and it should be kept in mind that the target value is 
lower than in type 1 or type 2 diabetes (see also Section 5.2.1).
6.3 Risk for hypoglycemia
The detected frequency of hypoglycemia is higher with CGM than with OGTT 
[65]. There is no prognostic relevance of hypoglycemia during OGT for later 
development of CFRD [66]. In general, it seems that the risk of hypoglycemia is not 
different from other types of diabetes and instruction on how to handle CFRD in 
daily life should address this risk.
7. CFRD and special situations
7.1 Pregnancy
With improved clinical course of CF and improved life expectancy, more female 
CF patients want to become pregnant. According to the UK guidelines [55], there 
are four groups.
• CFRD and IGT: optimized diabetes control and needs to be referred to a 
specialized diabetes team.
• NGT (tested in the last 3 months): OGT in first trimester and the next between 
week 24 and week 28.
• Unknown glycemic status: OGT before becoming pregnant, if possible.
7.2 Physical activity
With better clinical conditions, physical activities in all age groups of CF 
patients increased. Patients with CFRD should exercise and be educated about the 
risk of hypoglycemia, like other diabetic patients. CFRD is no reason to stop physi-
cal activities.
8.  CFRD and cystic fibrosis transmembrane regulator (CFTR) 
modulators
Since 2012, there is a new class of medication for CF patients on the market. 
These drugs are called “CFTR modulators.” They are CFTR mutation specific 
and are administered orally. This offers the chance that these drugs might affect 
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different organs that are reached by the bloodstream. The regulation of glucose 
homeostasis is a complex process and CFTR modulators might interfere at differ-
ent steps.
8.1 CFRD and ivacaftor
Ivacaftor is a CFTR potentiator and acts with gating mutations (e.g., G551D). 
It increases pulmonary function, weight, and quality of life (QoL) and decreases 
sweat chloride concentration [67].
In two siblings, insulin secretion and glucose AUC were measured during an 
OGTT before and 16 weeks after initiation of ivacaftor [12]. This paper described 
the beneficial effect of 4-month ivacaftor treatment on the pathologic OGTT of two 
patients with CF carrying the S549R gating mutation. This beneficial effect may 
be partially due to the increased earlier insulin secretion capacity [12]. Two other 
studies also reported an increase in insulin secretion after ivacaftor was initiated in 
CF patients with a gating mutation [68, 69]. As of now, reports have included only 
small numbers of patients and/or are uncontrolled studies. Sufficiently powered 
studies are still missing. In a registry study using data from the US and the UK 
with a follow-up of more than 5 years, a trend to a reduced prevalence of CFRD in 
ivacaftor-treated patients [14] was reported. If this observation will be corrobo-
rated in future studies, many CF patients would benefit from a postponed CFRD 
treatment burden.
8.2 CFRD and Ivacaftor/lumacaftor combination therapy
The combination therapy with ivacaftor/lumacaftor was administered to 
patients with the del F508 mutation [70]. The overall clinical effect regard-
ing pulmonary function, weight, and QoL was low compared to ivacaftor in 
patients with a gating mutation [67]. Using CGM and OGTT to control glucose 
homeostasis in five patients after initiation of ivacaftor/lumacaftor treatment, 
glycemic abnormalities persisted [71]. A consistent impact of the combination of 
ivacaftor/lumacaftor on insulin secretion or glucose tolerance was not detected in 
five patients [15]. In a very recent article from France [72], the change of OGTT 
categories after 1 year of lumacaftor/ivacaftor treatment was described in an 
uncontrolled study design. The reported improvement, for example, from CFRD 
to IGT is within the range of the well-known high variability of OGTT results in 
CF patients [73]. It is not surprising that the combination treatment, which had 
less of an effect on clinical outcome in gating mutations compared to ivacaftor, 
has so far no proven effect on CFRD, even if only a small number of CF patients 
were investigated.
8.3 CFRD and outlook
The recently published results with a triple combination CFTR modulator 
therapy in patients with a del phen 508 allele are impressive regarding pulmonary 
function increase, sweat chloride decrease, and other outcomes [74]. With a highly 
clinically effective CFTR modulator treatment and a sufficient number of patients, 
the demonstration of a positive influence on glucose homeostasis in a prospective 
study seems realistic.
However, there is currently no evidence-based information that CFTR modula-
tors have a relevant influence on the complex pathophysiology regarding glucose 
homeostasis.
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9. Conclusions
CFRD is still a highly relevant comorbidity in CF. Nevertheless, there are many 
questions regarding its optimal handling from both patients’ and physicians’ point 
of view. CFRD is a team approach, which includes the CF team but also the diabetes 
team.
Adherence to all aspects of CFRD diagnosis and treatment is low and needs 
urgent efforts to increase.
As long as no better screening procedure is established, 2h of OGTT should be 
used annually as screening for CFRD.
Education regarding CFRD should include patients, families, physicians, and the 
entire team.
Treatment as recommended by guidelines prefers only insulin. The recently 
published controlled prospective trials may endorse the use of oral antidiabetic 
drugs, at least in a subgroup of patients.
Monitoring must include all the measurements that are recommended for other 
types of diabetes. HbA1c target value for treatment should be lower than in type 1 or 
2 diabetes.
Typical microvascular complications are reported and patients should be 
regularly checked for these.
In future, the new and effective CFTR modulator therapies might also influ-
ence the prevalence of CFRD. In a perfect world, they might also improve glucose 
homeostasis in patients with CFRD and postpone CFRD entirely.
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